CPC A61K 31/496 (2013.01) [A61K 35/17 (2013.01); A61K 38/191 (2013.01); A61K 38/2013 (2013.01); A61K 38/2066 (2013.01); A61K 38/208 (2013.01); A61K 38/2086 (2013.01); A61K 38/217 (2013.01); A61K 39/0011 (2013.01); A61K 39/39 (2013.01); A61K 39/3955 (2013.01); A61K 47/6803 (2017.08); A61K 2039/6031 (2013.01); A61K 2039/6037 (2013.01); A61K 2039/6056 (2013.01); A61K 2039/6081 (2013.01)] | 12 Claims |
1. A method of treating a subject having or suspected of having a neoplastic disorder, comprising administering to the subject a therapeutically effective amount of Compound 1
![]() or a pharmaceutically acceptable salt thereof, and at least one additional therapy comprising a CTLA4 inhibitor, and wherein the neoplastic disorder is selected from myelodysplastic syndrome, chronic lymphocytic leukemia, acute lymphoblastic leukemia, chronic myelomonocytic leukemia, acute myeloid leukemia, and colon cancer.
|